Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett has received approval from the FDA for the company's supplemental abbreviated new drug application of phentermine hydrochloride capsules 30mg, a treatment for obesity.
Subscribe to our email newsletter
Phentermine hydrochloride (HCl) is indicated for the short-term management of obesity. The company expects to commence marketing this product immediately.
Arthur Bedrosian, president and CEO of Lannett, said: “This approval complements our phentermine HCI tablet 37.5mg which is the generic equivalent of Adipex-P, marketed by Gate Pharmaceuticals, a division of Teva Pharmaceutical Industries, and is an important addition to our product portfolio.”